Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

Abstract Background The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health. The use of antiviral drugs in patients with this disease have triggered people’s attentions. Whether interferon alfa-2b or lopinavir/ritonavir (LPV/r) plus interferon alfa-2b treatment...

Full description

Bibliographic Details
Main Authors: Jingyuan Liu, Chunjing Du, Lin Pu, Pan Xiang, Haofeng Xiong, Wen Xie, Zhihai Chen, Ang Li
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Infectious Diseases
Subjects:
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Virus
Pneumonia
Online Access:https://doi.org/10.1186/s12879-021-06595-6

Internet

https://doi.org/10.1186/s12879-021-06595-6

Similar Items